 |
|
|
| |
Ensitrelvir for mild-to-moderate COVID-19: Phase 3 part of Phase 2/3 study
|
| |
| |
CROI 2023 Feb 20-23
Takeki Uehara1, Hiroshi Yotsuyanagi2, Norio Ohmagari3, Yohei Doi4, Masaya Yamato5,
Takumi Imamura1, Takuhiro Sonoyama1, Takao Sanaki6, Yuko Tsuge1, Genki Ichihashi1, Hiroshi Mukae7
1. Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
2. The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
3. Disease Control and Prevention Center, National Center for Global Health, Tokyo, Japan
4. Departments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Japan
5. Department of General Medicine and Infectious Diseases, Rinku General Medical Center, Izumisano, Japan
6. Research Division, Shionogi & Co., Ltd., Osaka, Japan
7. Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
|
| |
|
|
|
|
|
